U.S. markets close in 1 hour 33 minutes
  • S&P 500

    4,182.19
    -39.67 (-0.94%)
     
  • Dow 30

    33,407.55
    -415.90 (-1.23%)
     
  • Nasdaq

    14,059.00
    -102.35 (-0.72%)
     
  • Russell 2000

    2,244.60
    -42.86 (-1.87%)
     
  • Crude Oil

    71.52
    +0.48 (+0.68%)
     
  • Gold

    1,772.50
    -2.30 (-0.13%)
     
  • Silver

    25.97
    +0.11 (+0.42%)
     
  • EUR/USD

    1.1875
    -0.0035 (-0.30%)
     
  • 10-Yr Bond

    1.4410
    -0.0700 (-4.63%)
     
  • GBP/USD

    1.3828
    -0.0096 (-0.69%)
     
  • USD/JPY

    110.1560
    -0.0750 (-0.07%)
     
  • BTC-USD

    36,172.01
    -1,566.06 (-4.15%)
     
  • CMC Crypto 200

    892.10
    -47.84 (-5.09%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 PM ET.

A live webcast of the presentation will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

Media Contact
Adam Silverstein, Ten Bridge Communications
adam@tenbridgecommunications.com
917.697.9313